World Trade Organization (WTO) members this week will hear a report on an informal meeting on an amendment to IP trade rules intended to allow easier access to medicines, which some argue has had a flawed design from its inception. The paragraph 6 amendment to the WTO TRIPS agreement allows drugs to be manufactured under compulsory license primarily for export.

As pointed out by Intellectual Property Watch, in many developing countries, there may not be a patent on a needed drug anyway. But having freedom from intellectual property rights does not help if there is no national capacity to manufacture the drug, and if an IP monopoly prevents a country with that manufacturing capacity [...]

OUVRIR MON COMPTE CREATE MY ACCOUNT

  Un problème avec cet article ? / A problem with this article?